LMR Partners’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,717
Closed -$298K 1568
2025
Q4
$298K Sell
1,717
-2,733
-61% -$498K ﹤0.01% 1216
2025
Q3
$848K Buy
4,450
+468
+12% +$83.1K ﹤0.01% 988
2025
Q2
$715K Sell
3,982
-21,301
-84% -$3.7M 0.01% 863
2025
Q1
$4.28M Sell
25,283
-13,396
-35% -$2.2M 0.04% 465
2024
Q4
$5.84M Buy
38,679
+32,093
+487% +$4.99M 0.05% 356
2024
Q3
$1.02M Buy
+6,586
New +$984K 0.01% 740
2020
Q3
Sell
-43,162
Closed -$4.92M 491
2020
Q2
$4.92M Buy
43,162
+36,545
+552% +$3.88M 0.12% 110
2020
Q1
$550K Buy
+6,617
New +$685K 0.03% 167
2017
Q4
Sell
-8,208
Closed -$768K 343
2017
Q3
$768K Sell
8,208
-17,475
-68% -$1.86M 0.08% 135
2017
Q2
$2.85M Buy
+25,683
New +$2.72M 0.18% 116
2017
Q1
Sell
-33,171
Closed -$3.05M 383
2016
Q4
$3.05M Buy
33,171
+18,150
+121% +$1.56M 0.47% 36
2016
Q3
$1.27M Buy
15,021
+2,349
+19% +$197K 0.12% 165
2016
Q2
$1.03M Buy
12,672
+7,272
+135% +$554K 0.16% 183
2016
Q1
$385 Buy
+5,400
New +$362K 0.04% 305
2015
Q3
Sell
-13,061
Closed -$947K 358
2015
Q2
$947K Sell
13,061
-2,026
-13% -$150K 0.12% 230
2015
Q1
$1.16M Buy
+15,087
New +$1.08M 0.16% 171

Other funds holding DGX

LMR Partners's DGX Position: Q1 2026 in Review

LMR Partners sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 1,717 shares — an estimated $298K sold.

LMR Partners first reported a position in DGX in Q1 2015 and held it in 16 quarters. The position peaked at $5.84M in Q4 2024. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • LMR Partners reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • LMR Partners sold 1,717 Quest Diagnostics shares in Q1 2026, an estimated $298K.
  • LMR Partners first reported a position in Quest Diagnostics in Q1 2015 and held it in 16 quarters.
  • LMR Partners's Quest Diagnostics position peaked at $5.84M in Q4 2024.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.